With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy By Mark TerryApril 25, 2023 Many biopharma companies had to place their clinical trials on hold during the first [….]
This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]
Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.
$7.50 per share
5 Questions with Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S. “5 Questions With……” is a new BioBuzz series where we reach out to interesting people [….]
5 Questions With John Trainer, CFO, NexImmune, Inc. “5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share [….]
New Immuno-Oncology Startup out of Baltimore Launches at JPM Healthcare Conference with Veteran Board, Advisors and Officers VerImmune’s Novel technology platform enables redirection of pre-existing natural immunity towards fighting cancer [….]
Three Examples of Commercializing Blockbuster Technologies from NCI
NextCure files for $92M IPO to advance Cancer Immunotherapy Pipeline April 29, 2019 NextCure, a clinical-stage biotech in Beltsville, MD developing cancer immunotherapies, announced the terms for its IPO that [….]
Q&A with Jaime Rodriguez-Canales, M.D., FEBP Dr. Rodriguez-Canales is a Senior Pathologist at MedImmune, and Course Director for the recent Multiplex Immunofluorescence in Immune-Oncology Symposium, a Bio-Trac program cosponsored by [….]
